Key takeaways

  • No quantitative dose rule: The Fifth Circuit rejected the notion that an expert witness must identify a threshold quantitative dose at which a chemical (or mixture) can cause injury to prove general causation. Instead, the Court held that an expert need only opine that exposure can cause harm at a level that a human could have realistically experienced. A supported range (such as toxicological profile, temporal factors, or occupational vs. non-occupational comparisons) suffices.
  • Chemical identification is required: The Court affirmed that an expert must identify the chemical to which the plaintiff was exposed and link that exposure to studies analyzing that chemical’s toxicity. An expert’s reliance on studies of a class or group of chemicals, without connecting the toxicological data to the chemical at issue, creates an “analytical gap” between the studies and the expert’s opinion.
  • Disease causation requires a direct link: The Court held that general causation requires reliance on studies that demonstrate disease-specific human relevance, not merely general carcinogenesis. The fact that a chemical has been classified as a carcinogen is not probative of the question of whether a plaintiff’s specific cancer phenotype can be caused by exposure to that chemical.

Background

Floyd Ruffin worked as a shoreline clean-up worker in Louisiana for five months after the 2010 Deepwater Horizon oil spill. Diagnosed with prostate cancer five years later, he brought a toxic tort claim against BP through the Deepwater Horizon medical-benefits class action settlement's Back-End Litigation Option (BELO), alleging that his exposure to polycyclic aromatic hydrocarbons (PAHs) caused his prostate cancer. BELO requires plaintiffs to prove the “legal cause of the claimed injury or illness is exposure to oil or other chemicals used during the response.” Under Fifth Circuit precedent, plaintiffs must satisfy both general causation—whether a chemical can cause the condition in the general population—and specific causation.

Plaintiff's expert testimony

Plaintiff's causation expert, a genetic and molecular epidemiologist, opined that Ruffin was exposed to polycyclic aromatic hydrocarbons (PAHs)—a class of over 200 distinct compounds found in crude oil with varying toxicological profiles. The plaintiff’s expert relied on studies showing that benzo(a)pyrene, one type of PAHs, was carcinogenic to humans, but insisted that his testimony concerned crude-oil exposure generally—not benzo(a)pyrene specifically. The expert’s ultimate opinion was that exposure to PAHs is capable of causing cancer in humans, and that Ruffin’s exposures were the cause of his prostate cancer.

District court ruling

The district court granted a Rule 702 motion and excluded Plaintiff’s expert testimony on general causation because it neither identified “the harmful level of exposure to a chemical” necessary to cause prostate cancer, nor proved Ruffin was actually exposed to that level. With no expert testimony to prove causation, the district court entered summary judgment.

Fifth Circuit analysis

Fifth Circuit rejects strict dose requirement

The Fifth Circuit rejected a strict quantitative dose requirement, departing from several unpublished Fifth Circuit decisions in BELO cases that had held experts were required to “determine not only whether a chemical can cause certain health effects, but also at what level of exposure those health effects appear.” Those decisions, lacking precedential force, relied on Allen v. Pennsylvania Engineering Corp., 102 F.3d 194, 199 (5th Cir. 1996).

The Fifth Circuit found Allen had been over-read. Allen required only evidence of “the harmful level of exposure to a chemical”—not a precise numerical floor.

The Fifth Circuit also cited Wright v. Willamette Industries, Inc., 91 F.3d 1105, 1107 (8th Cir. 1996), which rejected “a mathematically precise table equating levels of exposure with levels of harm.”

The Court explained that the proper general causation standard requires a reliable expert opinion that the specific chemical at issue can cause the disease at exposure levels a human could realistically experience. This standard does not demand a precise quantitative dose—it demands analytical reliability and an evidentiary connection to realistic exposure.

Expert exclusion affirmed based on analytical gaps

Despite rejecting a strict quantitative dose rule, the Fifth Circuit affirmed exclusion of the plaintiff's expert testimony due to “analytical gaps,” which undermined the general causation opinion and made the expert’s testimony unreliable.

Analytical gap one: Non-specific chemical analysis

General causation requires that the expert demonstrate the specific chemical to which the plaintiff alleges exposure can cause the plaintiff’s condition in the human population. The plaintiff-expert's causation opinion treated PAHs as a unified class, but his carcinogenicity data pertained only to benzo(a)pyrene—a single compound among the more than 200 chemicals within that class.

By the expert's own admission, benzo(a)pyrene is "probably the only" PAH confirmed to be a human carcinogen, yet neither Ruffin's complaint nor his expert's testimony identified benzo(a)pyrene as the chemical to which Ruffin was exposed. Plaintiff's expert equivocated on whether Ruffin encountered benzo(a)pyrene at all.

The expert repeatedly described PAHs as "the chemical at issue" while relying on benzo(a)pyrene data to support his general causation opinion. The Court found this mismatch—using data regarding one compound to support an opinion about a 200-compound class—to be an impermissible analytical leap that Rule 702 does not allow.

Analytical gap two: Cancer generalization

Even if benzo(a)pyrene was properly identified as the chemical at issue, the expert's general causation opinion failed on a second independent ground. General causation requires demonstrating that the specific chemical can cause the plaintiff's specific condition—here, prostate cancer—not merely cancer in general.

Plaintiff's expert relied on studies showing that benzo(a)pyrene causes tumors and skin papillomas in animals and is classified as a human carcinogen. The Court—citing Allen—held that a chemical's general carcinogen classification "is not probative of the question whether [the plaintiff's] cancer was caused by [the chemical]." Classification alone does not satisfy the general causation burden.

Plaintiff's expert's studies connecting the chemical to prostate cancer specifically relied again on broad PAH-exposure data rather than benzo(a)pyrene data—compounding the first analytical gap and leaving his general causation opinion without adequate evidentiary support at both levels of the analysis.

Conclusion

While the decision in Ruffin v. BP did not adopt a stringent dose quantification standard, it reinforced strict Rule 702 scrutiny on chemical specificity and disease-specific fit. Causation challenges in toxic tort cases increasingly turn on the analytical quality of the expert's methodology: whether the underlying studies address the relevant chemical’s toxicity and whether those studies link that chemical to the plaintiff's specific condition. As Ruffin demonstrates, challenging an opposing expert’s analytical rigor remains an important tool to defeating broad chemical-class theories at the summary judgment stage and at trial.

Contact